Finnair reports Q1 results on Apr 27. Finnair has lagged its peers in terms of pandemic recovery due...
We lowered our Q1 estimates, but with promising growth prospects from Q2 onwards, our 23-24E EBIT es...
Q1 results show market share gains and operation improvement '23e-'25e EBITDA up 1% Trading at 34x '...
UK outperforms our forecast EBITA up 4-6% for '23e-'25e We raise our fair value range to SEK 33-48 (...
Redeye updates its estimates and valuation following Vitec releasing its Q1 2023 report.
We expect a return to sales growth in '23eTough market but a reluctancy to hit the brakesImpressive ...
Q1e: EBIT of SEK 90mChinese NBSK import price down ~20% YTDFair value range: SEK 10-15/sh (11-16)Q1e...
Redeye updates its estimates on Safeture following the Q1 2023 report, which showed clear strides to...
Q1 came in better than expected on sales and ordersWe lower '23e-'25e EBIT by 12-6% on higher opex0.
Redeye briefly comments on IRRAS’ short-term financing that should add roughly another quarter to it...
Over the past week, several noteworthy events have occurred while Scandinavian Chemotech’s TO3 moves...
We maintain our estimates intact ahead of CapMan’s Q1 report due on 28 April.
We maintain our estimates intact ahead of Atria’s Q1 due on 25 April.
Q1 - något svagare finansiellt Hansa levererade under torsdagen sin Q1-rapport.
Bra resultat givet förutsättningarna BE Group rapporterade en underliggande EBIT på 10 mkr (180 mkr ...
Sales +2% vs. cons, adj. EBIT -2% Expect relatively unchanged estimates Conference call at 10:00 CET...
Vitrolife’s enters 2023 with good progress. The organic growth is 9%, with support from all three li...
-46% org. growth due to recent bad debt provision We lift '23e sales by 3% on recent order announcem...
Net sales SEK 476m, 3% vs ABGSCe Adj. EBITA SEK 64m, 4% vs ABGSCe On unrevised ests, share trading a...
Today, Stockwik announced changes to its long term financial targets, in which the company now seeks...
